Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study-Reference-Cited by-同舟云学术

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

Published:2009-07 Issue:9684 Volume:374 Page:126-135
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Henry Robert R,Lincoff A Michael,Mudaliar Sunder,Rabbia Michael,Chognot Cathy,Herz Matthias

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Diabetes. Fact sheet No 312,2008

2. Standards of medical care in diabetes—2008;Diabetes Care,2008

3. European guidelines on cardiovascular disease prevention in clinical practice: executive summary;Graham;Eur Heart J,2007

4. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes;Saydah;JAMA,2004

5. Effects of intensive glucose lowering in type 2 diabetes;Gerstein;N Engl J Med,2008

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease;International Journal of Molecular Sciences;2023-01-25

2. Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”;Clinical Drug Investigation;2023-01-12

3. A new insight into the treatment of diabetes by means of pan PPAR agonists;Chemical Biology & Drug Design;2022-01-17

4. Phytochemicals from Polyalthia Species: Potential and Implication on Anti-Oxidant, Anti-Inflammatory, Anti-Cancer, and Chemoprevention Activities;Molecules;2021-09-03

5. Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS);Science Bulletin;2021-08